NEW IMI PROJECT “GNA NOW” KICKS OFF ITS BATTLE AGAINST ANTIMICROBIAL RESISTANCE


Version
Download18
Total Views52
Stock
File Size1.27 MB
File Typepdf
Create Date1 August 2019
Last Updated1 August 2019
Download

BIOASTER announces the kick off a new IMI project "GNA NOW" (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), a public-private european R&D consortium.

The program will work on the development of novel antibacterial agents to battle antimicrobial resistance in gram-negative bacteria.

The multi-stakeholder consortium includes 9 other partners from academia, industry and SMEs: Nosopharm, BIOASTER, Helmholtz Centre for Infection Research, North Bristol National Health Service Trust, University of Liverpool, Inserm, Erasmus Medical Center, Medical University of Vienna, and Fraunhofer IME.